Tmunity Therapeutics is a clinical‑stage biotherapeutics company focused on delivering next‑generation T‑cell immunotherapy for cancer and other devastating diseases. The company integrates scientific, clinical and manufacturing expertise from its founders and collaborators to develop engineered T‑cell constructs. Tmunity has a diversified portfolio with three programs currently in clinic development and a pipeline aiming at both solid and liquid tumors. It operates laboratories and production facilities at the University of Pennsylvania and a dedicated cGMP manufacturing facility in East Norriton, PA, and collaborates with the Parker Institute, UCSF and Children’s Hospital of Philadelphia. The company emphasizes process improvement and production scale‑up to support clinical development and eventual commercialization. Tmunity’s leadership includes founders with prior CAR‑T experience and executives who helped bring the first CAR‑T therapy to market. Tmunity Therapeutics is a private clinical‑stage biotherapeutics company focused on delivering next‑generation T cell immunotherapy to patients with cancer, infectious disease and autoimmune disease. The company is developing a diversified portfolio of personalized T cell–based therapies designed to exert best‑in‑class control over T cell activation and direction in the body. Tmunity was founded on an exclusive collaboration and license agreement with the University of Pennsylvania and cites Carl H. June, M.D. among its scientific founders. It leverages laboratories and production facilities at UPenn and operates a dedicated cGMP manufacturing facility in Norristown, PA to pursue process improvement and scale production. The company aims to translate multiple engineered T cell approaches rapidly into the clinic, optimize manufacturing and pursue regulatory approvals. Its recent financing is intended to expand the business and operational structure to support development and manufacture of its portfolio. Tmunity Therapeutics develops engineered T cell therapies and platforms aimed at freeing the immunological potential of T cells to treat a wide range of disease indications. Its product focus includes T cell receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that provide control over T cell activation and direction in vivo. The company is also developing proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood, and tumors. Tmunity intends to use newly raised funds to advance development of these novel products. The company was co-founded by Anne Chew, Carl H. June, Bruce Levine, James L. Riley, Yangbing Zhao, and Bruce Blazar, who hold roles at Penn and the University of Minnesota. Tmunity is based in Philadelphia, PA.

Total raised

$185M

Funding rounds

3

Latest round

Series B

Latest activity

Oct 2019